Trust Company of Vermont’s Takeda Pharmaceutical TAK Stock Holding History

Trust Company of Vermont’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$5.77K	Hold	370	–	–	﹤0.01%	915
2025 Q3	$5.42K	Buy	+370	New	+$5.5K	﹤0.01%	912
2021 Q2	–	Sell	-100	Closed	-$2K	–	798
2021 Q1	$2K	Hold	100	–	–	﹤0.01%	724
2020 Q4	$2K	Hold	100	–	–	﹤0.01%	724
2020 Q3	$2K	Hold	100	–	–	﹤0.01%	709
2020 Q2	$2K	Hold	100	–	–	﹤0.01%	730
2020 Q1	$2K	Hold	100	–	–	﹤0.01%	825
2019 Q4	$2K	Hold	100	–	–	﹤0.01%	883
2019 Q3	$2K	Hold	100	–	–	﹤0.01%	948
2019 Q2	$2K	Hold	100	–	–	﹤0.01%	963
2019 Q1	$2K	Buy	+100	New	+$2.01K	﹤0.01%	927

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Trust Company of Vermont's TAK Position: Q4 2025 in Review

Trust Company of Vermont held its Takeda Pharmaceutical (TAK) position steady in Q4 2025 at 370 shares worth $5.77K. The position accounts for ﹤0.01% of the portfolio, ranked #915.

Trust Company of Vermont first reported a position in TAK in Q1 2019 and has held it in 11 quarters since. 349 funds tracked by Wall St. Rank hold TAK as of Q4 2025.

Trust Company of Vermont held 370 shares of Takeda Pharmaceutical worth $5.77K as of Q4 2025.
Trust Company of Vermont left its Takeda Pharmaceutical share count unchanged in Q4 2025.
Takeda Pharmaceutical made up ﹤0.01% of Trust Company of Vermont's portfolio in Q4 2025, its #915 holding.
Trust Company of Vermont first reported a position in Takeda Pharmaceutical in Q1 2019 and has held it in 11 quarters since.
349 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q4 2025.

Based on Trust Company of Vermont's 13F filing for Q4 2025, filed 16 Jan 2026.